clade c gp140
Vaccineexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 28, 2016 (NCT02685020)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- clade c gp140
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03307915 | Phase 1 | Mar 5, 2018 | Harvard University, Janssen Pharmaceutica NV, Ragon Institute of MGH, MIT and Harvard, United States Army |
| NCT03060629 | Phase 2 | Nov 1, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02935686 | Phase 2 | Mar 31, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02788045 | Phase 2 | Jul 8, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02685020 | Phase 1 | Mar 28, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 5 | 1 | 2 | 2016 |
| Johnson and Johnson | For profit | 4 | 4 | 2 | 2016 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Ragon Institute of MGH, MIT and Harvard | Academic/Hospital | 1 | 0 | 1 | 2018 |
| United States Army | Government | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1